| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 100mg | |||
| Other Sizes |
| ln Vitro |
Vinaginsenoside R4 exhibited melanogenic inhibitory activity in melan-a melanocytes. At a concentration of 80 µM, it inhibited melanin synthesis by 27.8%.
No cytotoxic effects were observed on melan-a cells at the tested concentrations (0–80 µM). No inhibition of in vitro mushroom tyrosinase activity was observed for the compound. [1] |
|---|---|
| ln Vivo |
Vinaginsenoside R4 showed inhibitory effects on body pigmentation in a zebrafish model.
At a concentration of 40 µM, it reduced melanin pigmentation on the surface of zebrafish embryos compared to the vehicle control. [1] |
| Cell Assay |
Melan-a melanocytes, an immortalized normal murine melanocyte cell line, were cultured in RPMI 1640 medium supplemented with fetal bovine serum, antibiotics, and phorbol 12-myristate 13-acetate (PMA).
Cells were treated with Vinaginsenoside R4 at concentrations ranging from 0 to 80 µM for 72 hours. Cell viability was assessed using a cell counting kit (CCK-8). For melanin quantification, treated cells were dissolved in sodium hydroxide, and lysates were measured spectrophotometrically at 450 nm. Data were normalized to protein content determined by a bicinchoninic acid (BCA) protein assay. [1] |
| Animal Protocol |
Zebrafish embryos were used as an in vivo model. Synchronized embryos were arrayed in multi-well plates containing embryo medium.
Vinaginsenoside R4 was dissolved in 0.1% dimethyl sulfoxide (DMSO) and added to the embryo medium from 9 to 72 hours post-fertilization. The final tested concentration was 40 µM. The medium was occasionally stirred and replaced daily. Body pigmentation was observed and photographed under a stereomicroscope. 1-Phenyl-2-thiourea (PTU) was used as a positive control. [1] |
| References | |
| Additional Infomation |
It has been reported that ginseng contains Vinaginsenoside R4, and there is relevant data reported.
Vinaginsenoside R4 was isolated from the leaves of hydroponically grown ginseng. It is a protopanaxadiol-type trisaccharide with a unique glycosidic bond located at the C-3 position, which is different from most protopanaxadiol-type ginsenosides (which usually have the sugar linked at the C-6-OH position). Its structure has been determined to be 3-O-[β-D-glucopyranosyl-(1→2)-β-D-glucopyranosyl]-20-O-β-D-glucopyranosyl-3β,6α,12β,20β-tetrahydroxydammar-23-ene. [1] |
| Molecular Formula |
C48H82O19
|
|---|---|
| Molecular Weight |
963.1533
|
| Exact Mass |
962.544
|
| CAS # |
156009-80-2
|
| PubChem CID |
15940177
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.0 g/cm3
|
| Boiling Point |
1041.4±0.0 °C at 760 mmHg
|
| Flash Point |
583.6±0.0 °C
|
| Vapour Pressure |
0.0±0.0 mmHg at 25°C
|
| Index of Refraction |
1.618
|
| LogP |
1.48
|
| Hydrogen Bond Donor Count |
13
|
| Hydrogen Bond Acceptor Count |
19
|
| Rotatable Bond Count |
13
|
| Heavy Atom Count |
67
|
| Complexity |
1720
|
| Defined Atom Stereocenter Count |
26
|
| SMILES |
CC(=CCC[C@@](C)([C@H]1CC[C@@]2([C@@H]1[C@@H](C[C@H]3[C@]2(C[C@@H]([C@@H]4[C@@]3(CC[C@@H](C4(C)C)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)C)O)C)O)C)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O)C
|
| InChi Key |
UOJAEODBOCLNBU-GYMUUCMZSA-N
|
| InChi Code |
InChI=1S/C48H82O19/c1-21(2)10-9-13-48(8,67-42-38(61)35(58)32(55)26(19-50)63-42)22-11-15-46(6)30(22)23(52)16-28-45(5)14-12-29(44(3,4)40(45)24(53)17-47(28,46)7)65-43-39(36(59)33(56)27(20-51)64-43)66-41-37(60)34(57)31(54)25(18-49)62-41/h10,22-43,49-61H,9,11-20H2,1-8H3/t22-,23+,24-,25+,26+,27+,28+,29-,30-,31+,32+,33+,34-,35-,36-,37+,38+,39+,40-,41-,42-,43-,45+,46+,47+,48-/m0/s1
|
| Chemical Name |
(2S,3R,4S,5S,6R)-2-[(2R,3R,4S,5S,6R)-2-[[(3S,5R,6S,8R,9R,10R,12R,13R,14R,17S)-6,12-dihydroxy-4,4,8,10,14-pentamethyl-17-[(2S)-6-methyl-2-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~16.67 mg/mL (~17.31 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.0383 mL | 5.1913 mL | 10.3826 mL | |
| 5 mM | 0.2077 mL | 1.0383 mL | 2.0765 mL | |
| 10 mM | 0.1038 mL | 0.5191 mL | 1.0383 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
